Your browser doesn't support javascript.
loading
Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists.
Sandbrink, Julian D; Johnson, Kyle; Gill, Maureen; Yaden, David B; Savulescu, Julian; Hannikainen, Ivar R; Earp, Brian D.
Afiliação
  • Sandbrink JD; University of Oxford.
  • Johnson K; Charité Universitätsmedizin Berlin.
  • Gill M; Yale University.
  • Yaden DB; Yale University.
  • Savulescu J; Johns Hopkins University School of Medicine.
  • Hannikainen IR; University of Oxford.
  • Earp BD; National University of Singapore.
AJOB Neurosci ; 15(2): 82-89, 2024.
Article em En | MEDLINE | ID: mdl-38315212
ABSTRACT
The psychedelic psilocybin has shown promise both as treatment for psychiatric conditions and as a means of improving well-being in healthy individuals. In some jurisdictions (e.g., Oregon, USA), psilocybin use for both purposes is or will soon be allowed and yet, public attitudes toward this shift are understudied. We asked a nationally representative sample of 795 US Americans to evaluate the moral status of psilocybin use in an appropriately licensed setting for either treatment of a psychiatric condition or well-being enhancement. Showing strong bipartisan support, participants rated the individual's decision as morally positive in both contexts. These results can inform effective policy-making decisions around supervised psilocybin use, given robust public attitudes as elicited in the context of an innovative regulatory model. We did not explore attitudes to psilocybin use in unsupervised or non-licensed community or social settings.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Alucinógenos / Transtornos Mentais Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: AJOB Neurosci Ano de publicação: 2024 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Alucinógenos / Transtornos Mentais Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: AJOB Neurosci Ano de publicação: 2024 Tipo de documento: Article País de publicação: Estados Unidos